Skip to main content

Advertisement

Table 1 Socio-demographic and clinical characteristics of the participants (N = 343)

From: Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy

Characteristic N %
Sex
 Male 87 25.4
 Female 256 74.6
Ethnicity
 Chinese 269 78.4
 Non-Chinese Asian 31 9.0
 Caucasian 43 12.5
Cancer diagnosis
 Breast cancer 174 50.7
 Lung cancer 48 14.0
 Gynecological cancer 46 13.4
 Head & Neck cancer 30 8.7
 Gastrointestinal cancer 29 8.5
 Urinary tract cancer 16 4.7
Cancer stage
 I 52 15.2
 II 99 28.9
 III 116 33.8
 IV 76 22.2
Treatment intent
 Curative 250 72.9
 Definitive 30 8.7
 Palliative 63 18.4
Type of chemotherapy
 Taxane 155 45.2
 Platinum 109 31.8
 Combination of taxane plus platinum 79 23.0
Chemotherapy protocol
 Docetaxel 122 35.6
 Paclitaxel 33 9.7
 Cisplatin/Carboplatin 80 23.4
 Oxaliplatin 28 8.3
 Carboplatin+Paclitaxel 49 14.4
 Carboplatin+Docetaxel 29 8.6